####  Curriculum Vitae

 **Behrouz Gharesi-fard** Date of Preparation: Sep 2024

|  |  |
| --- | --- |
| **PERSONAL DATA:** | Date of Birth: 1966Place of Birth: Shiraz-IranMarital Status: MarriedSex: Male |
| **ADDRESS:** | Immunology Department,Medical School, Shiraz University of Medical Sciences, Shiraz, Iran Tel/fax: +98-71-32351575, Mobile: 09173034180Email: gharesifb@sums.ac.ir |
| **EDUCATION:** | B.Sc. (Microbiology) 1990-1994**Kazeroon Azad University, Kazeroon, Iran.**M.Sc. (Medical immunology) 1995-1997**Shiraz University of Medical Sciences, Shiraz, Iran.**PhD (Medical immunology) 2005- 2010**Shiraz University of Medical Sciences, Shiraz, Iran.** |
| **INTERNATIONAL WorkshopS & TRAININGS:** | 1-Practical workshop in manual Immmuno- histochemistry with emphasis on process optimization by Dako Cytomation. Feb 2003. Tehran, Iran. 2-Practical workshop in HLA typing (PCR-SSP method) by Bio-test Company. Jun 2003. Tehran, Iran.3-Practical workshop in HLA typing (PCR-SSP method) and SSO and ELPHA system by Bio-test Company. May 2006. Dreieich. Germany.4- Practical workshop in HLA typing (Class I&II) by BAG Company. Feb 2007. Shiraz. Iran.5- Practical workshop in HLA I+II typing and blood group typing using the SSP technique by BAG Company. May 2008. Lich. Germany.6- Training course in proteomics technique (MALDI-TOF & LC-Mass). March-April 2010 NTU, Singapore.7- International training course in reproductive medicine technology. November 2010 Jena, Germany. |
| **REVIEWER:**  | 1- Iranian Journal of Immunology 2- Iranian Journal of Medical Sciences3- Iranian Red Crescent Medical Journal 4- Molecular Biology Reports5- International Journal of Immunogenetics6- Middle East journal of Cancer7- Obstetrics and Gynecology International8- Archives of Medical Research9- Archives of Gynecology and Obstetrics10- Avicenna Journal of Medical Biotechnology11- International Journal of Organ Transplantation Medicine12- International Journal of Fertility and Sterility13- Journal of Reproduction & Infertility14- American Journal of Reproductive Immunology15- Reproductive Sciences16- Human Reproduction17- PLOS ONE18- Placenta |
| **Membership:** | 1- Iranian Society for Immunology and Allergy2- International Society for Immunology of  Reproduction (ISIR) |
| **Awards:**  | 2010:  First Student, 2010 graduates of Shiraz University of Medical Sciences in Immunology2008: Elected student of PhD 2007: Elected student of PhD 1997:  First Student, 1997 graduates of Shiraz University of Medical Sciences in Immunology.1994: First Student, 1994 graduates of Kazeroon Azad University in Microbiology |

**TEACHING EXPERIENCES:**

1. **Immunity to Infectious Diseases** to MSc and PhD students.
2. **Immunohematology** to MSc students.
3. **Immunology** to Medical, Dentistry and Pharmacy students.
4. **Immunology** to Nurse and Midwifery students.
5. **Practical Immunology to** MSc and Ph.D students.
6. **Advance Immunology to** MSc and Ph.D students.
7. **HLA typing practical course to** MSc and Ph.D students.
8. **Reproductive Immunology to** MSc and Ph.D students.

**EMPLOYMENT:**

Academic member in Immunology Department. Shiraz University of Medical Sciences: from 2001 – 2010

Assistant professor in Immunology Department. Shiraz University of Medical Sciences: from 2010 –2014.

Associate professor in Immunology Department. Shiraz University of Medical Sciences: from 2014 –2019.

Professor in Immunology Department. Shiraz University of Medical Sciences: from 2019 –present.

Director of Immunology & HLA Lab Motahari Polyclinic, Shiraz University of Medical Sciences from 2010 – 2018

Director of stem cell bank, Motahari Polyclinic, Shiraz University of Medical Sciences from 2010 – 2021

Head of Immunology Department: Shiraz University of Medical Sciences, from 2013- 2019

Director of HLA typing section (Low and High resolution), Farzanegan Lab. Shiraz: From 2021 –present.

**ARTICLES:**

1. The expression and prognostic significance of c-erbB-2 molecules in patients with breast cancer in IRAN. **Gharesi-Fard B**, Vasaee M, Talaei A, Modjtahedi H, Dean C, Ghaderi A. A**. Iran J Med Sci,** 2000; 25(1&2):31-35.

2. Polymorphism of TNF-α promoter region in Iranian vaccines with BCG adenitis. E kamali-Sarvestani, A.R Nateghian, **B Gharesi-Fard**, A Behzadbehbahani, A Alborzi. **Iran J Med Sci**, 2001;26(1&2):22-27.

3.HLA-DRB1 alleles and the susceptibility of Iranian patients with breast cancer. Ghaderi A, Talei A, **Gharesi Fard B**, Farjadian Sh, Amirzargar A, Vasei M **Pathology Oncology Research**, 2001; 7(1):39-41.

4. P53 gene alteration and protein expression in Iranian women with infiltrative ductal breast carcinoma. AM Pezeshki, S Farjadian, A Talei, M Vasei, **B Gharesi-Fard**, M Doroudchi, A Ghaderi **Cancer Letter,** 2001; 161:69-75.

5. Production of prostate-specific antigen (PSA) by a breast cancer cell line, SK-Br-3. E kamali-Sarvestani, A Ghaderi, **B Gharesi-Fard**. **Med J IRI,** 2002; 16(1), 41-46.

6. Cytokine gene polymorphism in BCG lymphadenopathy. E kamali-Sarvestani, **B Gharesi-Fard**, A Alborzi. **Iran J Med Sci** , 2002; 27 (3): 125-130.

7. The expression of c-erbB-1 and c-erbB-2 in Iranian patients with Gastric carcinoma. A Ghaderi, M Vasei, S.A Maleck-Hosseini, **B Gharesi-Fard**, M Khodami, M Doroudchi, H Mojtahedi. **Pathology Oncology Research,** 2002; 8(4): 252-256.

8. The effect of maternal leukocyte immunization on NK cell activity in recurrent spontaneous abortion. Kamali Sarvestani E, **Gharesifard B**, Zolghadri J. **IRANIAN SOUTH MEDICAL JOURNAL,** 2003; 2(5): 124-128.

9. Evaluation of human leukocyte antigens in Papillon Lefevre syndrome. Lotf Azar M, **Gharesi Fard B**, Farjadian Sh. **Journal of Dentistry**. Tehran university of Medical Sciences, 2003; 15(4): 5-12.

10. The prevalence of anti-phospholipid syndrome in patients with recurrent pregnancy loss:A report from south of Iran. Zolghadri J, **Gharesi Fard B**, Parsa Nezhad ME, Alborzi S. **Med J IRI,** 2004; 18(2): 119-121.

11. Cytokine gene polymorphisms and susceptibility to recurrent pregnancy loss in Iranian women. E Kamali-Sarvestani, J Zolghadri, **B Gharesi-Fard**, J Sarvari. **J Reprod Immunology,** 2005 Apr; 65(2): 171-8.

12. Association of TNF-α and TNF-β Gene Polymorphism with Steroid Receptor Expression in Breast Cancer Patients. E Kamali-Sarvestani, **B Gharesi-Fard**, J Sarvari, A Talei. **Pathology Oncology Research,** 2005; 11(2): 99-102.

13. Interleukin-10 promoter polymorphisms and breast cancer risk in Iranian women. H Abdolrahim-Zadeh, N Hakkakian, R Asadollahi, **B Gharesi-Fard**, J Sarvari, E Kamali-Sarvestani, A Talei. **Iran J Immunol**, 2005; 2(3): 158-165.

14. Association study of IL-10 and IFN-gamma gene polymorphisms in Iranian women with preeclampsia. E Kamali-Sarvestani, S Kiany, **B Gharesi-Fard** , M Robati. **J Reprod Immunol**. 2006; 72(1-2):118-26.

15. Cytokine gene polymorphisms and susceptibility to cutaneous leishmaniasis in Iranian patients. E Kamali-Sarvestani, M Rasouli, H Mortazavi, **B Gharesi-Fard**.

**Cytokine.** 2006;35(3-4):159-65.

16. Investigation of Fcγ RIIA and Fcγ RIIIA Polymorphism in Multiple Sclerosis: A Case Control Study. AR Nikseresht , MA Azizi , **B Gharesi-Fard** , E Kamali Sarvestani. **Iran J Immunol**, 2006; 3(3): 136-141.

17. TNF-α, TNF-β and IL-4 gene polymorphisms in Iranian patients with multiple sclerosis. E Kamali-Sarvestani, AR Nikseresht, E Aflaki, J Sarvari, **B Gharesi-Fard**. **Acta Neurol Scand.** 2007; 115(3):161-166.

18. Effectiveness of leukocyte therapy in primary recurrent spontaneous abortion (RSA). **B Gharesi-Fard** , J Zolghadri, L Foroughinia, F Tavazoo, A Samsami Dehaghani. **Iran J Immunol**, 2007; 4(3): 173-178.

19. Effect of leukocyte therapy on tumor necrosis factor-alpha and interferon-gamma production in patients with recurrent spontaneous abortion. **B Gharesi-Fard** , J Zolghadri, E. kamali-Sarvestani. **Am J Reprod Immunol**. 2008;59(3):242-250.

20. Proteome differences of placenta between pre-eclampsia and normal pregnancy. **B Gharesi-Fard** , J Zolghadri, E. Kamali-Sarvestani. **Placenta**. 2010;31:121-125.

21. [Soluble CD30 in normal pregnancy, pre-eclampsia and recurrent pregnancy loss.](http://www.ncbi.nlm.nih.gov/pubmed/23268289) **Gharesi-Fard** B, Jafarzadeh L, Zolghadri J, Haghbin H. **Iran J Immunol**. 2012 Dec;9(4):234-40.

22. [Anti-Cardiolipin and Anti-Neutrophil Cytoplasmic Antibodies in Iranian Patients with Behcet's Disease.](http://www.ncbi.nlm.nih.gov/pubmed/23268290) Ataollahi MR, Aflaki E, Nazarinia MA, Shenavandeh S, Habibagahi Z, **Gharesi-**Fard B, Kamali-Sarvestani E. **Iran J Immunol**. 2012 Dec;9(4):241-7.

23. Presence of autoantibody against two placental proteins, Peroxiredoxin 3 (Prx3) & Peroxiredoxin 4 (Prx4) in sera of recurrent pregnancy loss (RPL) patients. **B Gharesi-Fard** , Jafarzadeh L, Ghader-shabankareh F, J Zolghadri, E. Kamali-Sarvestani. **Am J Reprod Immunol.** 2013 Mar;69(3):248-55.

24. [Soluble CD30 (sCD30) and effectiveness of leukocyte therapy in recurrent pregnancy loss patients.](http://www.ncbi.nlm.nih.gov/pubmed/23394737) **Gharesi-Fard B**, Zolghadri J, Haghbin H. **J Reprod Immunol**. 2013;97:240-44.

25. Presence of autoantibody against two placental proteins, Annexin A1 & Vitamin D binding protein, in sera of women with pre-eclampsia. **Gharesi-Fard B**, Ghader-shabankareh F, Jafarzadeh L, J Zolghadri, E. Kamali-Sarvestani. **J Reprod Immunol**. 2013; 99:10-16.

26. Importance of Anti-GRP78 antibody in pre-eclampsia. Rezanejad L, Zolghadri J, **Gharesi-Fard B. Iran J Immunol.** 2013: 10:238-46.

27. Absence of autoantibodies against oral and vascular-related cell lines in the sera of patients with Behcet's disease. [Ataollahi M](http://www.ncbi.nlm.nih.gov/pubmed?term=Ataollahi%20M%5BAuthor%5D&cauthor=true&cauthor_uid=24409661), [**Gharesi-Fard B**](http://www.ncbi.nlm.nih.gov/pubmed?term=Gharesi-Fard%20B%5BAuthor%5D&cauthor=true&cauthor_uid=24409661), [Aflaki E](http://www.ncbi.nlm.nih.gov/pubmed?term=Aflaki%20E%5BAuthor%5D&cauthor=true&cauthor_uid=24409661), Kamali-Sarvestani. [**Clin Lab.**](http://www.ncbi.nlm.nih.gov/pubmed/24409661) 2013;59 (11-12):1271-6.

28. Alteration in the expression of proteins in unexplained recurrent pregnancy loss compared with in the normal placenta. **Gharesi-Fard B**, Zolghadri J, Kamali-Sarvestani E. **J Reprod Dev.** 2014;60(4):261-7.

29. The effect of HLA-DRB1 sharing between the couples with recurrent pregnancy loss on the pregnancy outcome after leukocyte therapy. **Gharesi-Fard B,** Askarinejad-Behbahani R, Behdin S. **Iran J Immunol.** 2014;11(1):13-20.

30. HLA-DRBl and susceptibility to kidney allograft rejection in Southern Iranian patients. **Gharesi-Fard B,** Rezanezhad L, Karimi MH, Geramizadeh B, Salehipour MM, Hosseini SA, Roozbeh J**. Mol Biol Rep.** 2014;41(8):5513-8.

31. Distribution and Protective Role of HLAB40 in Iranian Patients with Kawasaki Disease; a Report from Southern Iran. Ajami Gh, Aflaki Kh, Alyasin S, **Gharesi-fard B,** Borzouee M, Amoozgar H. **Iran J Pediatr.** 2014;24(4):359-364.

32. Comparison of the analgesic effect of Ibuprofen and pulsed low‑level laser in reducing pain after orthodontic separator placement and evaluation of the changes in the sulcular pain especially prostaglandin E2 level. Oshagh M, Zarif Najafi H, Bahramnia F, **Gharesi-Fard B. Journal of Dental Lasers.** 2014; 8(2):44-49.

33. Differences in the Expression of TLRs and Inflammatory Cytokines in Pre-Eclamptic Compared with Healthy Pregnant Women. Dabagh-Gorjani F, Anvari F, Zolghadri J, Kamali-Sarvestani E, **Gharesi-Fard B**. **Iran J Immunol.** 2014 Dec;11(4):233-45.

34. Proteome Differences in the First- and Third-Trimester Human Placentas. **Gharesi-Fard B,** Zolghadri J, Kamali-Sarvestani E. **Reprod Sci.** 2015;22(4):462-68.

35. Preoxiredoxin family members (prx3 and prx4) and pregnancy disorder (recurrent pregnancy loss). **Gharesi-Fard B. Methods Mol Biol.** 2015;1208:299-311.

36. [Investigating the Association of IL-17A and IL-17F with Susceptibility to Pre-eclampsia in Iranian Women.](https://www.ncbi.nlm.nih.gov/pubmed/26119194) Anvari F, Dabagh-Gorjani F, Soltani-Zangbar MS, Kamali-Sarvestani E, Malek-Hosseini Z, **Gharesi-Fard** **B**. **Iran J Immunol**. 2015 Jun;12(2):117-28.

37. [The frequency of follicle stimulating hormone receptor gene polymorphisms in Iranian infertile men with azoospermia.](https://www.ncbi.nlm.nih.gov/pubmed/26730241) **Gharesi-Fard** **B**, Ghasemi Z, Shakeri S, Behdin S, Aghaei F, Malek-Hosseini Z. **Iran J Reprod Med**. 2015 Nov;13(11):673-8.

38. [Genomic DNA Extraction from Sperm](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=uW7KGC0AAAAJ&sortby=pubdate&citation_for_view=uW7KGC0AAAAJ:GnPB-g6toBAC). Anvar Z, Namavar-Jahromi B, Ebrahimi S, **Gharesi-Fard B. JAMSAT.** 2015; 1 (2), 120-121.

39. [Antisperm protein targets in azoospermia men.](https://www.ncbi.nlm.nih.gov/pubmed/27110078) Zangbar MS, Keshtgar S, Zolghadri J, **Gharesi-Fard** **B**. **J Hum Reprod Sci**. 2016 Jan-Mar;9 (1):47-52.

40. [Combined Effect of Trolox and EDTA on Frozen-Thawed Sperm Quality.](https://www.ncbi.nlm.nih.gov/pubmed/27217608) Keshtgar S, Iravanpour F, **Gharesi-Fard** **B**, Kazerooni M. **Iran J Med Sci**. 2016 May;41 (3):230-7.

41. [Altered Serum Cytokine Profiles in Relapse Phase of Relapsing-Remitting Multiple Sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/27671510) Peiravian F, Rajaian H, Samiei A, Gholijani N, **Gharesi-Fard** **B**, Mokaram P, Rahimi-Jaberi A, Kamali Sarvestani E. **Iran J Immunol**. 2016 Sep;13 (3):186-96.

42. [The Expression of T-Helper Associated Transcription Factors and Cytokine Genes in Pre-Eclampsia.](https://www.ncbi.nlm.nih.gov/pubmed/27999241) **Gharesi-Fard B**, Mobasher-Nejad F, Nasri F. **Iran J Immunol**. 2016 Dec;13 (4):296-308.

43. [Mesenchymal Stem Cells Upregulate the Expression of PD-L1 But Not VDR in Dendritic Cells.](https://www.ncbi.nlm.nih.gov/pubmed/27736253) Moravej A, Karimi MH, Geramizadeh B, Azarpira N, Zarnani AH, Yaghobi R, Khosravi M, Kalani M, **Gharesi-Fard** **B**. **Immunol Invest**. 2017 Jan; 46 (1): 80-96.

44. [Sperm DNA methylation of H19 imprinted gene and male infertility.](https://www.ncbi.nlm.nih.gov/pubmed/28295500) Nasri F, **Gharesi-Fard** **B**, Namavar Jahromi B, Farazi-Fard MA, Banaei M, Davari M, Ebrahimi S, Anvar Z. **Andrologia**. 2017 Dec;49 (10). doi: 10.1111/and.12766. Epub 2017 Mar 15.

45. [The Reaction of Placental GRP78 Protein with Sera from Women with Multiple Sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/29276183)

**Gharesi-Fard** **B**, Zare M, Kamali-Sarvestani E. **Iran J Immunol**. 2017 Dec;14 (4): 306-315.

46. [T helper cell subsets and related cytokines in infertile women undergoing in vitro fertilization before and after seminal plasma exposure.](https://www.ncbi.nlm.nih.gov/pubmed/29376019) Azad M, Keshtgar S, Jahromi BN, Kanannejad Z,

**Gharesi-Fard** **B**. **Clin Exp Reprod Med**. 2017 Dec;44(4):214-223.

**47.** [Interictal levels of calcitonin gene related peptide in gingival crevicular fluid of chronic migraine patients.](https://www.ncbi.nlm.nih.gov/pubmed/29654418) Fekrazad R, Sardarian A, Azma K, Karami M, Borhani-Haghighi A, **Gharesi-Fard B**, Movahedi B. Neurol Sci. 2018 Jul;39(7):1217-1223.

48. [Angiotensin Type 2 Receptor Gene Polymorphisms and Susceptibility to Preeclampsia.](https://www.ncbi.nlm.nih.gov/pubmed/30009143) Soltani-Zangbar MS, Pahlavani B, Zolghadri J, **Gharesi-Fard B**. **J Reprod Infertil**. 2018 Apr-Jun;19(2):95-99.

49. [The Impact of Methylenetetrahydrofolate Reductase (MTHFR) Sperm Methylation and Variants on Semen Parameters and the Chance of Recurrent Pregnancy Loss in the Couple.](https://www.ncbi.nlm.nih.gov/pubmed/30146842) Poorang S, Abdollahi S, Anvar Z, Tabei SMB, Jahromi BN, Moein-Vaziri N, **Gharesi-Fard** **B**, Banaei M, Dastgheib SA. **Clin Lab**. 2018 Jul 1;64(7):1121-1128.

50. [T Helper Cells Profile and CD4+CD25+Foxp3+Regulatory T Cells in Polycystic Ovary Syndrome.](https://www.ncbi.nlm.nih.gov/pubmed/30246693) Nasri F, Doroudchi M, Namavar Jahromi B, **Gharesi-Fard B**. **Iran J Immunol**. 2018 Sep;15(3):175-185.

51. [Difference in the seminal plasma protein expression in unexplained infertile men with successful and unsuccessful in vitro fertilisation outcome.](https://www.ncbi.nlm.nih.gov/pubmed/30276845) Kanannejad Z, **Gharesi-Fard B**. **Andrologia**. 2019 Feb;51(1):e13158.

52. [Altered Frequencies of CD4+ CD25+ Foxp3+ and CD8+ CD25+ Foxp3+ Regulatory T Cells in Pre-eclampsia.](https://www.ncbi.nlm.nih.gov/pubmed/30644698) cZare M, Doroudchi M, **Gharesi-Fard** **B**. **Iran J Allergy Asthma Immunol**. 2018 Dec 2;17(6):540-547.

53. [Influence of forkhead box protein 3 polymorphisms (rs2232365, rs3761548) with the outcome of pregnancy: A meta-analysis.](https://www.ncbi.nlm.nih.gov/pubmed/30784062) Hosseini Teshnizi S, Ali-Hassanzadeh M, **Gharesi-Fard** **B**, Kabelitz D, Kalantar K. **J Cell Physiol**. 2019 Feb 19. doi: 10.1002/jcp.28328. [Epub ahead of print]

54. [Association between Interleukin-32 and Interleukin-17A Single Nucleotide Polymorphisms and Serum Levels with Polycystic Ovary Syndrome.](https://www.ncbi.nlm.nih.gov/pubmed/30848577) Hesampour F, Namavar Jahromi B, Tahmasebi F, **Gharesi-Fard B**. **Iran J Allergy Asthma Immunol**. 2019 Feb;18(1):91-99.

55. I[nhibition of CatSper and Hv1 Channels and NOX5 Enzyme Affect Progesterone-Induced Increase of Intracellular Calcium Concentration and ROS Generation in Human Sperm.](https://www.ncbi.nlm.nih.gov/pubmed/30936599) Ghanbari H, Keshtgar S, Zare HR, **Gharesi-Fard** **B**. **Iran J Med Sci**. 2019 Mar;44(2):127-134.

56. [T Cell Subsets Profiling in Unexplained Infertile Women with Successful and Unsuccessful in Vitro Fertilization Outcome: Focus on the Effect of Seminal Plasma.](https://www.ncbi.nlm.nih.gov/pubmed/31066252) Kanannejad Z, Namavar Jahromi B, **Gharesi-Fard** **B**. **Iran J Allergy Asthma Immunol**. 2019 Apr 1;18(2):163-172.

57. [Serum and Peritoneal Fluid Cytokine Profiles in Infertile Women with Endometriosis.](https://www.ncbi.nlm.nih.gov/pubmed/31182689) Tarokh M, Ghaffari Novin M, Poordast T, Tavana Z, Nazarian H, Norouzian M, **Gharesi-Fard** **B**. **Iran J Immunol**. 2019 Jun;16(2):151-162.

58. [Analysis of the frequencies and functions of CD4+CD25+CD127low/neg, CD4+HLA-G+, and CD8+HLA-G+ regulatory T cells in pre-eclampsia.](https://www.ncbi.nlm.nih.gov/pubmed/31255887) Zare M, Namavar Jahromi B, **Gharesi-Fard** **B**. J **Reprod Immunol**. 2019 Jun;133:43-51.

59. [MDSCs in pregnancy: Critical players for a balanced immune system at the feto-maternal interface.](https://www.ncbi.nlm.nih.gov/pubmed/31703912) Ahmadi M, Mohammadi M, Ali-Hassanzadeh M, Zare M, **Gharesi-Fard** **B**. **Cell Immunol**. 2019 Dec;346:103990.

60. [Evaluation of IL-17 and IL-35 Serum Levels in Patients with Preeclampsia.](https://www.ncbi.nlm.nih.gov/pubmed/31897391) Batebi A, Namavar-Jahromi B, Ali-Hassanzadeh M, Ahmadi M, Hosseini MS, **Gharesi-Fard** **B**. **J Reprod Infertil**. 2019 Oct-Dec;20(4):237-243.

61. [The role of cytokines in depression and sleep regulation](https://www.scopus.com/record/display.uri?eid=2-s2.0-85099104346&origin=resultslist). [Nourimand, F](https://www.scopus.com/authid/detail.uri?authorId=57210914386), [Forouhari S, Tabei SZ,](https://www.scopus.com/authid/detail.uri?authorId=56557036400) Namavar Jahromi B Nami M, **Gharesi-Fard** **B,** [Mahmoudi A, Poordast T.](https://www.scopus.com/authid/detail.uri?authorId=57221413296) [**Pakistan Journal of Medical and Health Sciences**](https://www.scopus.com/sourceid/21100215707?origin=resultslist), 2020, 14(1), pp. 676–680.

62. [Analysis of the frequency of type 2 innate lymphoid cells and regulatory T cells in abortion-prone mice.](https://www.ncbi.nlm.nih.gov/pubmed/31945403) Ali-Hassanzadeh M, Hosseini MS, Ahmadi M, Zare M, Akbarzadeh-Jahromi M, Derakhshanfar A, **Gharesi-Fard** **B**. **Immunol Lett**. 2020 April;220:1-10.

63. Seminal plasma and CD4+ T-cell cytokine profiles in the in vitro fertilization success. Kanannejad Z, Namavar Jahromi B, **Gharesi-Fard B**. **Journal of Research in Medical Sciences.** 2020 Mar 25 (1), 26.

64. [CD52+ regulatory T cells and CD52-expressing sperms downregulated in couples with unexplained infertility: A case–control study](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=b90j1R0AAAAJ&sortby=pubdate&citation_for_view=b90j1R0AAAAJ:ZeXyd9-uunAC). M Raeisi, K Kalantar, BN Jahromi, **B Gharesi-Fard**.

**International Journal of Reproductive BioMedicine (IJRM)**, 385–387-385–387.

65. Stereological study of the placental structure in abortion-prone mice model (CBA/J× DBA/2J)

MS Hosseini, M Ali-Hassanzadeh, E Nadimi, S Karbalay-Doust. Noorafshan A, **Gharesi-Fard B**. **Annals of Anatomy-Anatomischer Anzeiger**, 2020 July 230:151508

66. Response Comment on "Association between Interleukin-32 and Interleukin-17A Single Nucleotide Polymorphisms and Serum Levels with Polycystic Ovary Syndrome". **Gharesi-Fard B**, Hesampour F. **Iran J Allergy Asthma Immunol**. 2020 Jun 23;19 (3):320-322.

67. Evaluation of Transforming Growth Factor-β1 and Interleukin-35 Serum Levels in Patients with Placenta Accreta. Khamoushi T, Ahmadi M, Ali-Hassanzadeh M, Zare M, Hesampour F, **Gharesi-Fard B**, Amooee S. **Lab Med**. 2020 Sep 14:lmaa071. doi: 10.1093/labmed/lmaa071. Online ahead of print. PMID: 32926163.

68. Proteome Analysis of CD4+ T Cells Reveals Differentially Expressed Proteins in Infertile Polycystic Ovary Syndrome Patients. Nasri F, Zare M, Doroudchi M, **Gharesi-Fard B.**  **Endocr Metab Immune Disord Drug Targets**. 2021. 21(11): 1998-2004.

69. T Cell Proliferative Responses and IgG Antibodies to β2GPI in Patients with Diabetes and Atherosclerosis. Monjezi MR, Fouladseresht H, Farjadian S, **Gharesi-Fard B**, Khosropanah S, Doroudchi M. **Endocr Metab Immune Disord Drug Targets**. 2021;21(3):495-503.

70. [Seminal plasma and CD4+ T-cell cytokine profiles in the *in vitro* fertilization success.](https://pubmed.ncbi.nlm.nih.gov/32419783/)

Kanannejad Z, Jahromi BN, **Gharesi-Fard B. J Res Med Sci.** 2020 Mar 18;25:26. doi: 10.4103

[Prevalence of HLA DQ 2, 8 in children with celiac disease](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=b90j1R0AAAAJ&sortby=pubdate&citation_for_view=b90j1R0AAAAJ:bFI3QPDXJZMC). SM Dehghani, N Dara, **B Gharesifard**, I Shahramian, F Dalili, M Salarzaei **Human antibodies.** 2021**:** 29 (2), 123-128.

71. [Evaluation of Transforming Growth Factor-β1 and Interleukin-35 Serum Levels in Patients with Placenta Accreta.](https://pubmed.ncbi.nlm.nih.gov/32926163/) Khamoushi T, Ahmadi M, Ali-Hassanzadeh M, Zare M, Hesampour F, **Gharesi-Fard B**, Amooee S. **Lab Med.** 2021 May 4;52(3):245-249.

72. [Proteome Analysis of CD4+ T Cells Reveals Differentially Expressed Proteins in Infertile Polycystic Ovary Syndrome Patients.](https://pubmed.ncbi.nlm.nih.gov/33213354/) Nasri F, Zare M, Doroudchi M, **Gharesi-Fard B**. Endocr Metab Immune Disord Drug Targets. 2021;21(11):1998-2004.

73. [Association between interleukin-32 gene polymorphism and susceptibility to preeclampsia.](https://pubmed.ncbi.nlm.nih.gov/34346819/)

Mazlum F, **Gharesi-Fard B**, Hadinedoushan H, Bakhshizadeh Ghashti Y. **Hypertens Pregnancy**. 2021 Aug;40(3):218-225.

74. [Investigating the Association between IL-27 and Susceptibility to Preeclampsia among Iranian Women.](https://pubmed.ncbi.nlm.nih.gov/34542965/) Aramesh A, Jahromi BN, Samadi M, **Gharesi-Fard B. Clin Lab.** 2021 Sep 1;67(9). doi: 10.7754.

75. [Are genetic variations in IL-1β and IL-6 cytokines associated with the risk of pre-eclampsia? Evidence from a systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/34275427/)

Nasri F, Zare M, Hesampour F, Ahmadi M, Ali-Hassanzadeh M, Mostafaei S, **Gharesi-Fard B**. J **Matern Fetal Neonatal Med.** 2022 Dec;35(25):6600-6609.

76. [Association of Human Leukocyte Antigen Alleles with Carbamazepine- or Lamotrigine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in an Iranian Population: A Case-control Study.](https://pubmed.ncbi.nlm.nih.gov/36688194/) Dastgheib L, Rostami F, **Gharesi-Fard B**, Asadi-Pooya AA, Namjoo S, Tahmasebi F, Hadibarhaghtalab M. **Iran J Med Sci**. 2023 Jan;48(1):70-76.

77. [Alteration in IFN-γ and CCL2 serum levels at first trimester of pregnancy contribute to development of preeclampsia and fetal growth restriction.](https://pubmed.ncbi.nlm.nih.gov/36720555/) Vafaei H, Faraji S, Ahmadi M, Tabei SMB, Fereidoni S, Shiravani Z, Hosseini SN, Asadi N, Kasraeian M, Faraji A, Abbasi O, **Gharesi-Fard B**. **Taiwan J Obstet Gynecol.** 2023 Jan;62(1):71-76.

78. [Apoptotic activity of Newcastle disease virus in comparison with nisin A in MDA-MB-231 cell line.](https://pubmed.ncbi.nlm.nih.gov/36816859/) Ghorbankhani GA, Mohammadi A, Kazemipur N, Morovati S, **Gharesi Fard B**, Nazifi Habibabadi S, Hashempour Sadeghian M.**Vet Res Forum**. 2023;14(1):29-37.

79. [Association between gene polymorphisms of IL-12, IL-12 receptor and IL-27 and organ involvement in Iranian endometriosis patients.](https://pubmed.ncbi.nlm.nih.gov/36328955/) Zare M, Hesampour F, Poordast T, Valibeigi M, Enayatmehri M, Ahmadi S, Nasri F, **Gharesi-Fard B. Int J Immunogenet.** 2023 Feb;50(1):24-33.

80. [In vitro-Generated MDSCs Reduce the Pregnancy Complications in an Abortion-Prone Murine Model.](https://pubmed.ncbi.nlm.nih.gov/35851683/) Ahmadi M, Ali-Hassanzadeh M, Hosseini MS, **Gharesi-Fard B. Reprod Sci.** 2023 Apr;30(4):1217-1228.

81. [Analysis of the Interaction of UBE2Q1 with B4GALT1 and P53: Experimental and Molecular Modeling Study](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=b90j1R0AAAAJ&sortby=pubdate&citation_for_view=b90j1R0AAAAJ:738O_yMBCRsC). Hadi Ghasemi, Atefeh Seghatoleslam, Mohammad A Fahmideh Kar, Laleh Mahbudi, Behrouz Gharesi Fard, Mahdi Jamshidi, **Protein and Peptide Letters**. 2023 30 (8), 668-678.

82. [COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.](https://pubmed.ncbi.nlm.nih.gov/38360719/) Kakavandi S, Hajikhani B, Azizi P, Aziziyan F, Nabi-Afjadi M, Farani MR, Zalpoor H, Azarian M, Saadi MI, **Gharesi-Fard B**, Terpos E, Zare I, Motamedifar M. **Cell Commun Signal**. 2024 Feb 15;22(1):126. doi: 10.1186/s12964-023-01316-9.

83. [Comparison of Maternal IgG Antibody from Infected SARS-CoV-2 Mothers to Newborns in the 2nd and 3rd Trimesters: A Cohort Study](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=b90j1R0AAAAJ&sortby=pubdate&citation_for_view=b90j1R0AAAAJ:tOudhMTPpwUC). M Kasraeian, M Zarekhafri, H Vafaei, **B Gharesi-Fard**, A Faraji, N Asadi, **Women’s Health Bulletin**. 2024 11 (2), 120-127.

84. [Potential therapeutic properties of broccoli extract and soy isoflavones on improvement endometriosis and involved oxidative parameters.](https://pubmed.ncbi.nlm.nih.gov/39041387/) Sabetian S, Archin Dialameh P, Tanideh N, **Gharesi-Fard B**, Ahmadi M, Valibeigi M, Kumar PV, Siahbani S, Namavar Jahromi B. **Horm Mol Biol Clin Investig.** 2024 Jul 23. doi: 10.1515/hmbci-2023-0071.

**PRESENTATIONS:**

**4th Iranian Congress of Immunology and Allergy. Isfahan, Iran 13-15 May 1998:**

1. Association between HLA-DRB1\*12 allele and Iranian patients with breast cancer. Farjadian Sh, Amirzagar A, **Gharesi-Fard B**, Talei A, Ghaderi A.

2. Immunohistochemical investigation of breast cancer for the expression of HLA class-I antigen and their significance for prognosis. Talei A, Vasei M, **Gharesi-Fard B**, Ghaderi A.

3. Immunohistochemical investigation of breast cancer for the expression of c-erbB-1 & c-erbB-2 and their significance for prognosis. **Gharesi-Fard B**, Vasei M, Talei A, Modjtahedi H, Dean C, Salabian M, Ghaderi A.

**The first Iranian Congress of Cancer Resaerch. Urmia. Iran 15-18 may 2001:**

1. Prognostic value of ER, PR, c-erbB-1 and c-erbB-2 molecules in breast cancer. Talei A, **Gharesi-Fard B**, Vasei M, Modjtahedi H, Ghaderi A.

2.Association between HLA-DRB1\*12 allele and Iranian patients with breast cancer. **Gharesi-Fard B**, Amirzagar A, Farjadian Sh, Ghaderi A.

3. Expression of c-erbB-1 and c-erbB-2 oncogens in gastric carcinoma and their prognostic significance. Maleckhosseini A, **Gharesi-Fard B**, Vasei M, khodami M, Modjtahedi H, Ghaderi A.

4. Over expression of P53 in breast cancerand its prognostic significance. Pezeshki A, Talei A, Vasei M, **Gharesi-Fard B**, Farjadian Sh, Ghaderi A.

5. Expression of prostate-specific antigen (PSA) in the breast cancer cell line, SK-Br-3. E kamali-Sarvestani, A Ghaderi, **B Gharesi-Fard**.

**11**th **International congress of Immunology. Stockholm, Sweden 22-27 July 2001:**

1. Promoter region polymorphism of TNF-α gene in patients with three different autoimmune diseases. E Kamali-Sarvestani, **B Gharesi-Fard**, E Aflaki, SH Samangoui, A Nikseresht, HR Zare.

2. Polymorphism of TNF-α promoter region in Iranian vaccines with BCG adenitis. A Nateghian, A Alborzi, A Golchin, **B Gharesi-Fard**, E Kamali-Sarvestani.

3. Polymorphism of TNF-α promoter region in Iranian patients with breast cancer. A Talei, **B Gharesi-Fard**, N Bavoli, A Golchin, E Kamali-Sarvestani.

4. Polymorphism of TNF-α promoter region in patients with cutaneous leishmaniasis. M Rasouli, **B Gharesi-Fard**, A Gorgi, M Ziaee, E Kamali-Sarvestani.

5. TNF-α promoter region polymorphism in recurrent spontaneous abortion (RSA). **B Gharesi-Fard**, J Zolghadri, E Kamali-Sarvestani.

**6th Iranian Congress of Immunology and Allergy.Tehran, Iran 7-9 May 2002:**

1. Frequency of bi-allelic polymorphisms in four different cytokine gene and their genotype frequency in southern Iranian population. **B Gharesi-Fard**, N Bavoli-Raftar, M Rasouli, J Sarvari, E Kamali-Sarvestani.

2. P53 gene alteration and protein expression in Iranian women with infiltrative ductal breast carcinoma. A.M Pezeshki, S Farjadian, A Talei, M Vasei,

**B Gharesi-Fard**, M Doroudchi, A Ghaderi.

3. Different pattern of cytokine production between recurrent spontaneous abortion (RSA) patients and normal controls during One-way mixed lymphocyte culture (MLC) with her partner,s mononuclear cells. **B Gharesi-Fard**, J Zolghadri, H.R Zare, M Rasouli, E Kamali-Sarvestani.

4. The polymorphism in IL-4 promoter region (C-590T) in Iranian patients with Breast cancer. N Bavoli-Raftar, M Rasouli, **B Gharesi-Fard**, J Sarvari, A Talei, E Kamali-Sarvestani.

5. The polymorphism of TNF-α promoter region (-308) and the first intron of lymphotoxin alpha (LT-α) gene (+252) in Iranian patients with breast cancer. N Bavoli-Raftar, M Rasouli, **B Gharesi-Fard**, A Talei, E Kamali-Sarvestani.

6. Polymorphism of TNF-α promoter region and NcoI polymorphism in the first intron of LT-α gene in Iranian vaccines with BCG adenitis. **B Gharesi-Fard**, Bavoli-Raftar, M Rasouli, A Alborzi, A Behzadbehbahani, A.R Nateghian, E Kamali-Sarvestani.

7. Autoantibody production before and after paternal leukocyte immunization in the cases with recurrent spontaneous abortion. **B Gharesi-Fard**, J Zolghadri, Z Malek-Hosseini, A Ghaderi.

8. Cytokine gene polymorphisms in women with recurrent spontaneous abortion. **B Gharesi-Fard**, J Zolghadri, M Rasouli, N Bavoli-Raftar, J Sarvari, E Kamali-Sarvestani.

9. The effect of paternal leukocyte immunization on NK cell activity in recurrent spontaneous abortion (RSA). E Kamali-Sarvestani, H.R Zare, J zolghadri, **B Gharesi-Fard**, M Rasouli, N Bavoli-Raftar.

10. Polymorphisms of IL-10 and IL-4 gene promoter region in patients with healing and chronic cutaneous Leishmaniasis (CL). M Rasouli, N Bavoli-Raftar, h Mortazavi, **B Gharesi-Fard**, E Kamali-Sarvestani.

11. Polymorphism of TNF-α promoter region (-308) and the first intron of lymphotoxin alpha (LT-α) gene (+252) in Iranian patients with MS. A.R Nikseresht, **B Gharesi-Fard**, J Server, M Rasouli, N Bavoli-Raftar, E Kamali-Sarvestani.

12. Polymorphisms in the TNF-α (-308) gene promoter and first intron of LT-α (+252) gene in patients cutaneous Leishmaniasis (CL). M Rasouli, N Bavoli-Raftar, J sarvari, **B Gharesi-Fard**, E Kamali-Sarvestani.

13. In vivo evaluation of Cell-Mediated Immunity (CMI) in cutaneous leishmaniasis (CL) before and after healing by leishmanin skin test (LST). M Rasouli, N Bavoli-Raftar, J sarvari, **B Gharesi-Fard**, A Gorgi, E Kamali-Sarvestani.

**XXI Congress of the European Academy of Allergology and Clinical Immunology. Naples, Italy 1-5 June 2002:**

1. Polymorphism of TNF-α promoter region (-308) and the first intron of lymphotoxin alpha (LT-α) gene (+252) in Iranian patients with MS. A.R Nikseresht, **B Gharesi-Fard**, J Server, M Rasouli, N Bavoli-Raftar, E Kamali-Sarvestani.

2. Polymorphism of TNF-α promoter region (-308) and the first intron of lymphotoxin alpha (LT-α) gene (+252) in Iranian patients with breast cancer. N Bavoli-Raftar, M Rasouli, **B Gharesi-Fard**, A Talei, E Kamali-Sarvestani.

3. Cytokine gene polymorphisms in women with recurrent spontaneous abortion. E Kamali-Sarvestani, **B Gharesi-Fard**, J Zolghadri, J Sarvari.

**XXII Congress of the European Academy of Allergology and Clinical Immunology. Paris, France 7-11 June 2003:**

1. Cytokine gene polymorphisms in Iranian patients with recurrent spontaneous abortion (RSA).Z Modjtahedi, J Zolghadri, J Sarvari, **B Gharesi-Fard**, E Kamali-Sarvestani.

2. T+874A polymorphism in the firest intron of IFN-γ gene in preeclampsia. S kiany, **B Gharesi-Fard**, E Kamali-Sarvestani.

3. Cytokine gene polymorphisms in Iranian patients with RA. E Aflaki, J Sarvari, **B Gharesi-Fard**, E Kamali-Sarvestani.

4. Cytokine gene polymorphisms in Iranian patients with SLE. E Kamali-Sarvestani, E Aflaki, J Sarvari, **B Gharesi-Fard.**

5. Polymorphisms in the TNF-α promoter region (-308) and the first intron of LT-α gene (+252) in Iranian patients with breast cancer. **B Gharesi-Fard**, A Monabati, J Sarvari, E Kamali-Sarvestani.

1. 6. Polymorphisms at the TNF loci, IL-4 and IL-10 promoter region in BCG lymphadenopathy. J Sarvari, **B Gharesi-Fard**, E Kamali-Sarvestani.

**The first international congress of cancer genetics, 13-16 Dec, 2003 Tehran, Iran:**

1. HLA calss I gene polymorphism and susceptibility of Iranian women with breast cancer.

M Razmkhah, A Talei, M Doroudchi, **B Gharesi-Fard**, A Ghaderi.

**7th Iranian Congress of Immunology and Allergy.Mashhad, Iran 4-7 May 2004:**

1. The Importance of C-590T IL-4 promoter polymorphism in the expression of lupus arthropathy. E Aflaki, **B Gharesi-Fard**, J Sarvari, E kamali-Sarvestani.

2. The Importance of IL-4 (C-590T) promoter polymorphism in the expression of secondary progressive form of MS. **B Gharesi-Fard**, A.R Nikseresht, M.A Azizi, J Sarvari, E kamali-Sarvestani.

3. Polymorphisms in the TNF-α promoter region (-308) and the first intron of LT-α gene (+252) in Iranian patients with Nasal Polyposis (NP). B Khademi, J Sarvari, F Eghtedari, S Kashef, M.H Imanieh, F Handjani, **B Gharesi-Fard**, E Kamali-Sarvestani.

4. Interferon Gamma (IFN-γ) +874 T/A gene polymorphism in Iranian patients with MS. A.R Nikseresht, **B Gharesi-Fard**, M.A Azizi, J Sarvari, E kamali-Sarvestani.

5. Cytokine gene polymorphisms in southern Iranian population. **B Gharesi-Fard**, J Sarvari, N Ezadi, A Amini, E kamali-Sarvestani.

6. IL-10 gene promoter and IFN-γ first intron polymorphism in Iranian women with preeclapsia. S kiany, M Robati, J Sarvari, **B Gharesi-Fard**, M Taalom, E kamali-Sarvestani.

7. FC receptor for immunoglobulin G (FcγR): A role in the pathogenesis of MS. E kamali-Sarvestani, A.R Nikseresht, M.A Azizi, J Sarvari, **B Gharesi-Fard**.

8. Mixed Lymphocyte Reaction (MLC) in Iranian women with preeclampsia. S kiany, M Robati, **B Gharesi-Fard**, M Taalom, J Sarvari, E kamali-Sarvestani.

9. IFN-γ production by peripheral blood mononuclear cells of Iranian preeclamptic women after PHA stimulation. S kiany, **B Gharesi-Fard**, M Robati, J Sarvari, M Taalom, E Kamali-Sarvestani.

10. Cytokine gene polymorphisms and susceptibility to recurrent pregnancy loss in Iranian women. J Zolghadri, **B Gharesi-Fard**, J Sarvari, S Kiany, E Kamali-Sarvestani.

11. HLA Class I polymorphism and susceptibility of Iranian women with breast cancer. M Razmkhah, A Talei, M Doroudchi, **B Gharesi-Fard**, A Ghaderi.

**12th International Congress of Immunology and 4th Annual Conference of FOCIS**

**Montreal, Quebec Canada 18-23 July 2004:**

1. The lmportance of C-590T IL-4 Promoter Polymorphism in the Expression of Lupus Arthropthy. E flaky, **B Gharesi-Fard**, J Sarvari, E Kamali-Sarvestani.

2. The Importance of IL-4 (-590C→T) Promoter polymorphism in the Expression of Secondary Progressive Form of Multiple Sclerosis (MS). S Najafipour, AR Nikseresht, MA Azizi, J Sarvari, **B Gharesi-Fard**, E Kamali-Sarvestani.

3. Cytokine Gene Polymorphisms in Southern Iranian Population. **B Gharesi-Fard,** J Sarvari, E kamali-Sarvestani.

4. Interferon gamma (IFN-γ) +874T/A Gene Polymorphism in Iranian Patients with Multiple Sclerosis (MS). E Kamali-Sarvestani, AR Nikseresht, MA Azizi, J Sarvari, **B Gharesi-Fard.**

5. Interleukin-10 Gene promoter and Interferon-Gamma Fisrt Intron Polymorphisms in Iranian Women with Preeclampsia. S Kiany, M Robati, J Sarvari, **B Gharesi-Fard,** M Taalom, E kamali-Sarvestani.

6. Polymorphism in Tumor Necrosis factor-Alpha (TNF-α) promoter Region

(-308) and the First Intron of Lymphotoxin-Alpha (LT- α) Gene (+252) in Iranian Patients with Nasal Polyposis (NP). J Sarvari, B Khademi, F Eghtedari, S Kashef, MH imanieh, F Handjani, **B Gharesi-Fard**, E Kamali-Sarvestani.

7. Cytokine Gene Polymorphisms and Susceptibility to Recurrent Pregnancy Loss (RPL) in Iranian Women. J Zolghadri, **B Garesi-Fard**,J Sarvari, S Kiany, E kamali-Sarvestani.

**7th Iranian Congress of Immunology and Allergy.Mashhad, Iran 4-7 May 2004:**

1. The Importance of C-590T IL-4 promoter polymorphism in the expression of lupus arthropathy. E Aflaki, **B Gharesi-Fard**, J Sarvari, E kamali-Sarvestani.

2. The Importance of IL-4 (C-590T) promoter polymorphism in the expression of secondary progressive form of MS. **B Gharesi-Fard**, A.R Nikseresht, M.A Azizi, J Sarvari, E kamali-Sarvestani.

3. Polymorphisms in the TNF-α promoter region (-308) and the first intron of LT-α gene (+252) in Iranian patients with Nasal Polyposis (NP). B Khademi, J Sarvari, F Eghtedari, S Kashef, M.H Imanieh, F Handjani, **B Gharesi-Fard**, E Kamali-Sarvestani.

4. Interferon Gamma (IFN-γ) +874 T/A gene polymorphism in Iranian patients with MS. A.R Nikseresht, **B Gharesi-Fard**, M.A Azizi, J Sarvari, E kamali-Sarvestani.

5. Cytokine gene polymorphisms in southern Iranian population. **B Gharesi-Fard**, J Sarvari, N Ezadi, A Amini, E kamali-Sarvestani.

6. IL-10 gene promoter and IFN-γ first intron polymorphism in Iranian women with pre-eclampsia. S kiany, M Robati, J Sarvari, **B Gharesi-Fard**, M Taalom, E kamali-Sarvestani.

7. FC receptor for immunoglobulin G (FcγR): A role in the pathogenesis of MS. E kamali-Sarvestani, A.R Nikseresht, M.A Azizi, J Sarvari, **B Gharesi-Fard**.

8. Mixed Lymphocyte Reaction (MLC) in Iranian women with preeclampsia. S kiany, M Robati, **B Gharesi-Fard**, M Taalom, J Sarvari, E kamali-Sarvestani.

9. IFN-γ production by peripheral blood mononuclear cells of Iranian preeclamptic women after PHA stimulation. S kiany, **B Gharesi-Fard**, M Robati, J Sarvari, M Taalom, E Kamali-Sarvestani.

10. Cytokine gene polymorphisms and susceptibility to recurrent pregnancy loss in Iranian women. J Zolghadri, **B Gharesi-Fard**, J Sarvari, S Kiany, E Kamali-Sarvestani.

11. HLA Class I polymorphism and susceptibility of Iranian women with breast cancer. M Razmkhah, A Talei, M Doroudchi, **B Gharesi-Fard**, A Ghaderi.

**XXXIII Meting of the International Society for Oncodevelopmental Biology and Medicine (ISOBM 2005), Rhodes, Greece 24-29 September 2005.**

1 .Cytokine gene polymorphisms in Iranian patients with breast cancer. **B Gharesi-Frad**, A Talei, E kamali-Sarvestani.

**8th Iranian Congress of Immunology and Allergy.Tehran, Iran 16-18 May 2006:**

1. Investigation of -1377 G/A and -670 A/G polymorphisms of the Apo-1/Fas promoter in SLE patients. J Arasteh, E Aflaki, **B Gharesi-Fard**, Z Amirghofran and E Kamali-Sarvestani.

**X ISIR Congress, Opatija, Croatia, 10-14 June 2007:**

1. Effect of leukocyte therapy on alteration of cytokine production and its relation to pregnancy outcome. **B Gharesi-Fard**, J Zolghadri , E Kamali-Sarvestani.

**14th IFPA Conference, Seggau Castle, Austria, 10-13 Sep 2008:**

1. The effect of HLA-DRB1 sharing between RSA couples on pregnanct outcome after leukocyte therapy. **B Gharesi-Fard**, J Zolghadri , S Farjadian.

**7th European Congress on Reproductive Immunology, Marathon, Greece**

**17-20 Sep 2009:**

1. Soluble CD30 (sCD30) in Normal pregnancy, Pre-eclampsia and recurrent spontaneous abortion (RSA)**. B Gharesi-Fard**, J Zolghadri , F Tavazoo

**8th European Congress on Reproductive Immunology, Munich, Germany**

**11-13 Nov 2010:**

1. Placental proteome of unexplained recurrent pregnancy loss (URPL).**B Gharesi-Fard**, J Zolghadri , E Kamali-Sarvestani

**9th European Congress on Reproductive Immunology, Copenhagen, Denmark**

**23-26Aug 2011:**

1. Placental proteome differences in first compared to third trimester normal pregnancy. **B Gharesi-Fard**, J Zolghadri , E Kamali-Sarvestani

**International congress of ASRI & ESRI, Hamburg, Germany 31 May-2 Jun 2012:**

1. Presence of autoantibody against two placental proteins, Prx3 & Prx4 in sera of recurrent pregnancy loss patients. **B Gharesi-Fard**, F Ghaderi-shabankareh, L Jafarzadeh, J Zolghadri , E Kamali-Sarvestani

2. Presence of autoantibody against two placental proteins, Annexin A1 & Vitamin D binding protein in sera of recurrent pregnancy loss patients. **B Gharesi-Fard**, F Ghaderi-shabankareh, L Jafarzadeh, J Zolghadri , E Kamali-Sarvestani.

**13th ICB & 5th ICBMB congress. Yazd, Iran 16-19 April 2013:**

1. Follicle stimulating hormone receptor (FSHR) gene polymorphisms in women with PCOS. Keshtgar N, Negahban L, Zolghadri J, **Gharesi-Fard B,** Azadi R.

**12th Iranian Congress of Immunology and Allergy. Tehran, Iran 16-18 May 2014:**

1. Anti-GRP78 antibody and pre-eclampsia. **Gharesi-Fard B,** Rezanejhad L, Zolghadri J.

2. The effect of HLA-DRB1 sharing between the couples with recurrent pregnancy loss on the pregnancy outcome after leukocyte therapy. **Gharesi-Fard B,** Askarinejad-Behbahani 3, Behdin Sh.

3. Follicle stimulating hormone receptor (FSHR) gene polymorphisms and susceptibility to azoospermia in Iranian infertile men. Sharifpour S, Ghasemi Z, Shakeri S, Hadaegh A, Zolghadri J, **Gharesi-Fard B.**

4. Investigation of the association between IL-17A & IL-17F gene polymorphisms and susceptibility to pre-eclampsia (PE) in Iranian women. Anvari F, Dabagh-Gorjani F, Soltani-zangbar MS, Zolghadri J, Kamali-Sarvestani E, **Gharesi-Fard B.**

5. Different expression of TLR-2 and TLR-4 in placentas from women complicated with pre-eclampsia compared with healthy pregnant women. Dabagh-Gorjani F, Anvari F, Zolghadri J, Kamali-Sarvestani E, **Gharesi-Fard B.**

6. Anti-sperm protein targets in azoospermia men. Soltani Zangbar M, Keshtgar S, Zolghadr J, **Gharesi-Fard B.**

**13th human proteome organization world congress. Spain, Madrid 5-8 Oct 2014:**

1. Proteome of the human full term placenta. **B Gharesi-Fard,** E Kamali-Sarvestani.

**21th world congress of COGI. China, Guilin 7-10 May 2015:**

1-Investigation of the association between il-17A & IL-17F and susceptibility to pre-eclampsia (PE) in Iranian women.

1. **th Iranian Congress of Immunology and Allergy. Tabriz, Iran 26-29 April 2016:**

1. Presence of antibody against placental HSP70 protein in serum of women afflicted with Multiple Sclerosis.

**14th International Congress of Immunology and Allergy, ICIA 2018, Tehran, Iran 26-28 April, 2018**

1. Different expression of IL-6 and TNF-α in placenta from women complicated with pre-eclampsia compared with healthy pregnant women.

2. A Novel Sperm Protein Target in Azoospermia Men.

**5th European congress of Immunology, Sep 2018, Netherlands 2-5 Sep 2018**

1. Difference in protein expression of the peripheral blood CD4+ T lymphocytes between polycystic ovary syndrome and healthy women.

2. T helper cells profile and CD4+CD25+Foxp3+ regulatory T cells in Polycystic Ovary Syndrome (PCOS).

3. T helper cell subsets and related cytokines in infertile women undergoing in vitro fertilization before and after seminal plasma exposure.